奥沙利铂抗肿瘤及其耐药机制的研究进展(4)

[18]Lee JH,Um JW,Lee JH,et al.Can immunohistochemistry of multidrug-resistant proteins replace the histoculture drug response assay in colorectal adenocarcinomas?[J].Hepatogastroenterology,2012,59(116):1075-1078.

[19]Zhang W,Trachootham D,Liu J,et al.Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia[J].Nat Cell Biol,2012,14(3):276-86.

[20]Mathieu A,Remmelink M,D’Haene N,et al.Development of a chemoresistant orthotopic human nonsmall cell lung carcinoma model in nude mice:Analyses of tumor heterogenity in relation to the immunohistochemical levels of expression of cyclooxygenase-2,ornithine decarboxylase,lung-related resistance protein,prostaglandin e synthetase,and glutathione-s-transferase-alpha (gst)-alpha,gst-mu,and gst-pi[J].Cancer,2004,101(8):1908-1918.

[21]Tozawa K,Oshima T,Kobayashi T,et al.Oxaliplatin in treatment of the cisplatin-resistant mkn45 cell line of gastric cancer[J].Anticancer Res,2008,28(4B):2087-2092.

[22]Pendyala L,Creaven PJ,Perez R,et al.Intracellular glutathione and cytotoxicity of platinum complexes[J].Cancer Chemother Pharmacol,1995,36(4):271-278.

[23]Arnould S,Hennebelle I,Canal P,et al.Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines[J].Eur JCancer,2003,39(1):112-119.

[24]Preston TJ,Henderson JT,Mc Callum GP,et al.Base excision repair of reactive oxygen species-initiated 7,8-dihydro-8-oxo-2’-deoxyguanosine inhibits the cytotoxicity of platinum anticancer drugs[J].Mol Cancer Ther,2009,8(7):2015-2026.

[25]Sharma S,Shah NA,Joiner AM,et al.DNA polymerase zeta is a major determinant of resistance to platinum-based chemotherapeutic agents[J].Mol Pharmacol,2012,81(6):778-787.

[26]Park DJ,Stoehlmacher J,Zhang W,et al.A xeroderma pigmentosum group d gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer[J].Cancer Res,2001,61(24):8654-8658.

[27]Lai JI,Tzeng CH,Chen PM,et al.Very low prevalence of xpd k751q polymorphism and its association with xpd expression and outcomes of folfox-4 treatment in asian patients with colorectal carcinoma[J].Cancer sci,2009,100(7):1261-1266.

[28]Ruzzo A,Graziano F,Loupakis F,et al.Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line folfox-4 chemotherapy[J].J Clin Oncol,2007,25(10):1247-1254.

[29]Kim DY,Paek TY,Oh SY,et al.Pretreatment selection of regimen according to genetic analysis improves the efficacy of chemotherapy in the first line treatment of metastatic colorectal cancer[J].J Surg Oncol,2014,109(3):250-254.

[30]Cubillo A,Rodriguez-Pascual J,Lopez-Rios F,et al.Phase ii trial of target-guided personalized chemotherapy in first-line metastatic colorectal cancer[J].Am J Clin Oncol,2016,39(3):236-242.

[31]Prewett M,Deevi DS,Bassi R,et al.Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab[J].Clin Cancer Res,2007,13(24):7432-7440.

[32]Lin L,Li X,Pan C,et al.Atxn2l upregulated by epidermal growth factor promotes gastric cancer cell invasiveness and oxaliplatin resistance[J].Cell Death Dis,2019,10(3):173.

[33]Cossa G,Gatti L,Cassinelli G,et al.Modulation of sensitivity to antitumor agents by targeting the mapk survival pathway[J].Curr Pharm Des,2013,19(5):883-894.

[34]He W,Liang B,Wang C,et al.Msc-regulated lncrna macc1-as1 promotes stemness and chemoresistance through fatty acid oxidation in gastric cancer[J].Oncogene,2019,38(23):4637-4654.

[35]Hayward RL,Macpherson JS,Cummings J,et al.Enhanced oxaliplatin-induced apoptosis following antisense bcl-xl down-regulation is p53 and bax dependent:Genetic evidence for specificity of the antisense effect[J].Mol Cancer Ther,2004,3(2):169-178.

[36]Kollmannsberger C,Mayer F,Kuczyk M,et al.Treatment of patients with metastatic germ cell tumors relapsing after highdose chemotherapy[J].World J Urol,2001,19(2):120-125.

[37]Almendro V,Ametller E,Garcia-Recio S,et al.The role of mmp7 and its cross-talk with the fas/fasl system during the acquisition of chemoresistance to oxaliplatin[J].PLo S One,2009,4(3):e4728.

[38]Chaney SG,CampbellSL,Temple B,et al.Protein interactions with platinum-DNA adducts:From structure to function[J].J Inorg Biochem,2004,98(10):1551-1559.

[39]Lebwohl D,Canetta R.Clinical development of platinum complexes in cancer therapy:An historical perspective and an update[J].Eur J Cancer,1998,34(10):1522-1534.

[40]Rixe O,Ortuzar W,Alvarez M,et al.Oxaliplatin,tetraplatin,cisplatin,and carboplatin:Spectrum of activity in drugresistant cell lines and in the cell lines of the national cancer institute’s anticancer drug screen panel[J].Biochem Pharmacol,1996,52(12):1855-1865.

[41]Ibrahim A,Hirschfeld S,Cohen MH,et al.Fda drug approval summaries:Oxaliplatin[J].Oncologist,2004,9(1):8-12.

[42]Culy CR,Clemett D,Wiseman LR.Oxaliplatin.A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies[J].Drugs,2000,60(4):895-924.

百度搜索“77cn”或“免费范文网”即可找到本站免费阅读全部范文。收藏本站方便下次阅读，免费范文网，提供经典小说医药类奥沙利铂抗肿瘤及其耐药机制的研究进展(4)在线全文阅读。